Overview

On December 15, 2017, Teva Pharmaceuticals (TEVA) announced the exclusive launch of the generic version of 300 mg Viread tablets in the United States. TEVA stock gained nearly 7.6% on the day. The Vanguard FTSE All-World ex-US ETF (VEU) rose by ~0.22% on the day. VEU holds ~0.07% of its total portfolio holdings in TEVA.

TEVA Stock Price Rises on Generic Launch of Viread

Viread is the registered trademark of Gilead Sciences (GILD) for Tenofovir disoproxil fumurate medication, which is used for the treatment of chronic Hepatitis B and HIV (human immunodeficiency virus). Gilead’s patent on Viread expired on December 15, 2017. Viread received FDA (US Food and Drug Administration) approval in 2001. Teva and Gilead entered a patent settlement deal in 2013, which included Gilead’s HIV antivirals Truvada and Atripla as well, in addition to Viread. The generic version launches of the other two drugs are slated for fiscal 2018. Teva had a number of new product launches planned for 2017, as shown in the diagram. However, the company witnessed a delay in certain launches. As a result, it saw lower-than-expected sales contributions from the new launches.

During its recent quarterly results on November 2, 2017, Teva reduced its full fiscal 2017 guidance on its sales contribution from new product launches to $400 million from $500 million.

What is Tenofovir disoproxil fumurate?

Tenofovir disoproxil fumarate tablets are used for the treatment of HIV-1 infection for patients over two years old and the treatment of chronic Hepatitis B in adults and pediatric patients who are 12 years old or older. The medication is indicated for use in combination with other ARV (antiretroviral) drugs. As of October 2017, Viread sales amounted to approximately $762 million in the United States, as per IMS data.

Merck (MRK) and Bristol-Myers Squibb (BMY) are the two other major players in the HIV drugs market in the United States.

Latest articles

23 Jul

Google Ups the Ante for Ad Targeting

WRITTEN BY Ruchi Gupta

Google has announced that it's going to start adding third-party ad targeting and browser privacy restrictions to Google Chrome.

23 Jul

Will Fortinet Beat Q2 Earnings Estimates?

WRITTEN BY Aditya Raghunath

Leading cybersecurity company Fortinet (FTNT) is scheduled to announce its second-quarter earnings results on August 1. What should we expect?

Harley-Davidson’s Q2 earnings were slightly better than estimates.

Netflix (NFLX) has long relied on international markets to drive its streaming video business growth.

23 Jul

Could Ford’s Q2 Earnings Push Its Stock Even Higher?

WRITTEN BY Mohit Oberoi, CFA

Ford's second-quarter earnings results are scheduled for release on July 24. So far, Ford stock has outperformed its legacy peers.

23 Jul

Why RBC Isn't Optimistic about BlackBerry Stock

WRITTEN BY Aditya Raghunath

Shares of BlackBerry (BB) have been volatile over the last 12 months. BlackBerry stock fell 40.5% from $12.0 in September 2018 to $6.57 in December.